The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
The rally attracted around 250 riders, including professionals and amateurs.
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
To address the preventive & primary healthcare delivery gaps in India
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
Subscribe To Our Newsletter & Stay Updated
